BK0579 Biomedical
- 791.575
- +1.887+0.24%
Zhongsheng Pharmaceutical (002317): Based on traditional Chinese medicine, innovation leads R&D in an orderly manner
Zhixiang Jintai (688443) 2024EHA BCMAXCD3 dual antibody data review: IL17 with excellent BCMA dual antibody data is about to be approved
Baipsis (301080): Regular business maintains high growth, global layout strategy continues to deepen
Hairong Cold Chain (603187) Company Brief Evaluation Report: Steady Domestic Sales & Strong Growth in Export Sales, Significant Improvement in Profitability
Kaisai Biotech (688065): Promoting R&D investment and capacity building to accumulate growth momentum
Fosun Pharmaceutical (600196): Continuing to promote innovation and transformation
Bide Pharmaceutical (688073): Overseas advantages continue to be optimistic about improving quality and efficiency
Changchun Hi-Tech (000661): Growth hormone maintains resilience and continues to advance in the research pipeline
Eddy Pharmaceutical (688488) Company Brief Review Report: Sales of innovative drugs continue to improve and enter a stage of rapid growth
Dizhe Pharmaceutical (688192): The first year of commercialization has begun
Gloria Ying (002821): Overall Q1 operations are steady, and annual results are expected to maintain steady growth
Jet Biotech (688026): Short-term pressure on performance is expected to resume growth in 2024
Alice (688578): Continued release of core products
Biotech (688177): Steady progress in commercialization promotion around the world
Haichuang Pharmaceutical (688302): Continued progress in drugs under development
Zhixiang Jintai (688443): Major milestones have been made in various products
Gloria Ying (002821): Steady growth in regular business, buybacks show confidence in development
Xianju Pharmaceutical (002332): Continued dosage of formulations, accelerated internationalization and upgrading of raw materials
Kain Technology (688687) In-depth Report: Kailiwei, a new hepatitis C drug, is expected to create a second growth curve by selling probiotics derived from the new hepatitis B drug currently being developed by China and China
Huadong Pharmaceutical (000963): Innovation and gradual implementation of differentiated product pipelines are worth looking forward to